• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

家族性高胆固醇血症的遗传异质性:对分子诊断的影响。

Genetic Heterogeneity of Familial Hypercholesterolemia: Repercussions for Molecular Diagnosis.

机构信息

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, 80131 Naples, Italy.

CEINGE-Biotecnologie avanzate Franco Salvatore, 80145 Naples, Italy.

出版信息

Int J Mol Sci. 2023 Feb 6;24(4):3224. doi: 10.3390/ijms24043224.

DOI:10.3390/ijms24043224
PMID:36834635
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9961636/
Abstract

Genetics of Familial Hypercholesterolemia (FH) is ascribable to pathogenic variants in genes encoding proteins leading to an impaired LDL uptake by the LDL receptor (LDLR). Two forms of the disease are possible, heterozygous (HeFH) and homozygous (HoFH), caused by one or two pathogenic variants, respectively, in the three main genes that are responsible for the autosomal dominant disease: , and genes. The HeFH is the most common genetic disease in humans, being the prevalence about 1:300. Variants in the gene causes FH with a recessive inheritance and a specific variant was described as causative of FH, contributing to increase FH genetic heterogeneity. In addition, variants in genes causing other dyslipidemias showing phenotypes overlapping with FH may mimic FH in patients without causative variants (FH-phenocopies; , , and genes) or act as phenotype modifiers in patients with a pathogenic variant in a causative gene. The presence of several common variants was also considered a genetic basis of FH and several polygenic risk scores (PRS) have been described. The presence of a variant in modifier genes or high PRS in HeFH further exacerbates the phenotype, partially justifying its variability among patients. This review aims to report the updates on the genetic and molecular bases of FH with their implication for molecular diagnosis.

摘要

家族性高胆固醇血症 (FH) 的遗传学归因于编码导致 LDL 受体 (LDLR) 摄取受损的 LDL 的蛋白的致病性变异。该病有两种形式,即杂合子 (HeFH) 和纯合子 (HoFH),分别由三个主要基因中的一个或两个致病性变异引起,这三个主要基因负责常染色体显性疾病: , 和 基因。HeFH 是人类最常见的遗传性疾病,患病率约为 1:300。 基因中的变异导致常染色体隐性遗传的 FH,并且已经描述了一种特定的 变异是 FH 的致病原因,导致 FH 遗传异质性增加。此外,导致表现型与 FH 重叠的其他血脂异常的基因变异可能在没有致病变异的患者中模拟 FH(FH 表型模拟物; , , 和 基因),或者在携带致病基因变异的患者中作为表型修饰物。几种常见变异也被认为是 FH 的遗传基础,已经描述了几种多基因风险评分 (PRS)。HeFH 中修饰基因的变异或高 PRS 进一步加重了表型,部分解释了其在患者中的可变性。本综述旨在报告 FH 的遗传和分子基础的最新进展及其对分子诊断的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1a/9961636/1b63e1d1659e/ijms-24-03224-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1a/9961636/1b63e1d1659e/ijms-24-03224-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1a/9961636/1b63e1d1659e/ijms-24-03224-g001.jpg

相似文献

1
Genetic Heterogeneity of Familial Hypercholesterolemia: Repercussions for Molecular Diagnosis.家族性高胆固醇血症的遗传异质性:对分子诊断的影响。
Int J Mol Sci. 2023 Feb 6;24(4):3224. doi: 10.3390/ijms24043224.
2
Unraveling the genetic background of individuals with a clinical familial hypercholesterolemia phenotype.解析具有临床家族性高胆固醇血症表型个体的遗传背景。
J Lipid Res. 2024 Feb;65(2):100490. doi: 10.1016/j.jlr.2023.100490. Epub 2023 Dec 18.
3
Molecular genetics of familial hypercholesterolemia in Israel-revisited.以色列家族性高胆固醇血症的分子遗传学研究回顾。
Atherosclerosis. 2017 Feb;257:55-63. doi: 10.1016/j.atherosclerosis.2016.12.021. Epub 2016 Dec 18.
4
Familial hypercholesterolemia: A complex genetic disease with variable phenotypes.家族性高胆固醇血症:一种具有可变表型的复杂遗传性疾病。
Eur J Med Genet. 2020 Apr;63(4):103831. doi: 10.1016/j.ejmg.2019.103831. Epub 2019 Dec 25.
5
Genetic Analysis of Japanese Children Clinically Diagnosed with Familial Hypercholesterolemia.日本临床诊断为家族性高胆固醇血症儿童的遗传分析。
J Atheroscler Thromb. 2022 May 1;29(5):667-677. doi: 10.5551/jat.62807. Epub 2021 May 20.
6
Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.载脂蛋白 B 代谢途径相关基因致病性变异在日本杂合子家族性高胆固醇血症患者中的影响。
Atherosclerosis. 2019 Oct;289:101-108. doi: 10.1016/j.atherosclerosis.2019.08.004. Epub 2019 Aug 19.
7
A Low-Frequency APOB p.(Pro955Ser) Variant Contributes to the Severity of/Variability in Familial Hypercholesterolemia.一种低频载脂蛋白B p.(Pro955Ser)变异体与家族性高胆固醇血症的严重程度/变异性有关。
J Clin Endocrinol Metab. 2023 Jan 17;108(2):422-432. doi: 10.1210/clinem/dgac572.
8
ABCG5 and ABCG8 genetic variants in familial hypercholesterolemia.家族性高胆固醇血症中的 ABCG5 和 ABCG8 基因突变。
J Clin Lipidol. 2020 Mar-Apr;14(2):207-217.e7. doi: 10.1016/j.jacl.2020.01.007. Epub 2020 Jan 29.
9
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.意大利家族性高胆固醇血症患者的突变谱:LIPIGEN研究的新结果。
Atheroscler Suppl. 2017 Oct;29:17-24. doi: 10.1016/j.atherosclerosissup.2017.07.002.
10
The familial hypercholesterolaemia phenotype: Monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes.家族性高胆固醇血症表型:单基因家族性高胆固醇血症、多基因高胆固醇血症和其他原因。
Clin Genet. 2020 Mar;97(3):457-466. doi: 10.1111/cge.13697.

引用本文的文献

1
Hepatic Inactivation of Carnitine Palmitoyltransferase 1a Lowers ApoB-Containing Lipoproteins in Mice.肝脏中肉碱棕榈酰转移酶1a的失活降低小鼠体内含载脂蛋白B的脂蛋白水平
Arterioscler Thromb Vasc Biol. 2025 Aug;45(8):1368-1388. doi: 10.1161/ATVBAHA.125.322473. Epub 2025 Jun 12.
2
Long noncoding RNAs in familial hypercholesterolemia: biomarkers, therapeutics, and AI in precision medicine.家族性高胆固醇血症中的长链非编码RNA:精准医学中的生物标志物、治疗方法及人工智能
Lipids Health Dis. 2025 May 21;24(1):182. doi: 10.1186/s12944-025-02605-7.
3
Improved Genetic Characterization of Hypercholesterolemia in Latvian Patients with Familial Hypercholesterolemia: A Combined Monogenic and Polygenic Approach Using Whole-Genome Sequencing.

本文引用的文献

1
Lysosomal Acid Lipase Deficiency: Genetics, Screening, and Preclinical Study.溶酶体酸性脂肪酶缺乏症:遗传学、筛查和临床前研究。
Int J Mol Sci. 2022 Dec 8;23(24):15549. doi: 10.3390/ijms232415549.
2
A new 165-SNP low-density lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia.基于新一代测序的新的 165-SNP 低密度脂蛋白胆固醇多基因风险评分在家族性高胆固醇血症的常规诊断中优于先前发表的评分。
Transl Res. 2023 May;255:119-127. doi: 10.1016/j.trsl.2022.12.002. Epub 2022 Dec 15.
3
LDLR missense variants disturb structural conformation and LDLR activity in T-lymphocytes of Familial hypercholesterolemia patients.
拉脱维亚家族性高胆固醇血症患者高胆固醇血症的基因特征改善:一种使用全基因组测序的单基因和多基因联合方法
Int J Mol Sci. 2024 Dec 16;25(24):13466. doi: 10.3390/ijms252413466.
4
Earlyonset Parkinsons disease with mutations in both the gene and the gene: A case report.同时具有基因和基因双突变的早发性帕金森病:一例报告。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Apr 28;49(4):637-642. doi: 10.11817/j.issn.1672-7347.2024.230438.
5
Impact of 12-SNP and 6-SNP Polygenic Scores on Predisposition to High LDL-Cholesterol Levels in Patients with Familial Hypercholesterolemia.12个单核苷酸多态性和6个单核苷酸多态性多基因评分对家族性高胆固醇血症患者高LDL-胆固醇水平易感性的影响。
Genes (Basel). 2024 Apr 6;15(4):462. doi: 10.3390/genes15040462.
6
The impact of overweight on lipid phenotype in different forms of dyslipidemia: a retrospective cohort study.超重对不同类型血脂异常脂质表型的影响:一项回顾性队列研究。
J Endocrinol Invest. 2024 Dec;47(12):3111-3118. doi: 10.1007/s40618-024-02368-5. Epub 2024 Apr 11.
7
Low Density Lipoprotein Cholesterol Decreases the Expression of Adenosine A Receptor and Lipid Rafts-Protein Flotillin-1: Insights on Cardiovascular Risk of Hypercholesterolemia.低密度脂蛋白胆固醇降低腺苷 A 受体和脂筏蛋白 flotillin-1 的表达:高胆固醇血症心血管风险的新见解。
Cells. 2024 Mar 11;13(6):488. doi: 10.3390/cells13060488.
8
Genetic testing for familial hypercholesterolemia.家族性高胆固醇血症的基因检测。
Curr Opin Lipidol. 2024 Apr 1;35(2):93-100. doi: 10.1097/MOL.0000000000000925. Epub 2024 Jan 31.
9
Membrane Transporter of Serotonin and Hypercholesterolemia in Children.儿童的血清素和高胆固醇血症的膜转运体。
Int J Mol Sci. 2024 Jan 7;25(2):767. doi: 10.3390/ijms25020767.
10
Diagnosis of Familial Hypercholesterolemia in Children and Young Adults.儿童和青少年家族性高胆固醇血症的诊断。
Int J Mol Sci. 2023 Dec 25;25(1):314. doi: 10.3390/ijms25010314.
载脂蛋白 B100 基因突变干扰家族性高胆固醇血症患者 T 淋巴细胞的结构构象和 LDLR 活性。
Gene. 2023 Feb 15;853:147084. doi: 10.1016/j.gene.2022.147084. Epub 2022 Dec 1.
4
New Trends and Therapies for Familial Hypercholesterolemia.家族性高胆固醇血症的新趋势与治疗方法
J Clin Med. 2022 Nov 9;11(22):6638. doi: 10.3390/jcm11226638.
5
A mechanism-based operational definition and classification of hypercholesterolemia.基于机制的高胆固醇血症的操作性定义和分类
J Clin Lipidol. 2022 Nov-Dec;16(6):813-821. doi: 10.1016/j.jacl.2022.09.006. Epub 2022 Sep 30.
6
Whole genome sequence analysis of blood lipid levels in >66,000 individuals.对超过 66000 个人的血脂水平进行全基因组序列分析。
Nat Commun. 2022 Oct 11;13(1):5995. doi: 10.1038/s41467-022-33510-7.
7
New algorithms for treating homozygous familial hypercholesterolemia.用于治疗纯合子家族性高胆固醇血症的新算法。
Curr Opin Lipidol. 2022 Dec 1;33(6):326-335. doi: 10.1097/MOL.0000000000000853. Epub 2022 Oct 4.
8
Genetic and molecular architecture of familial hypercholesterolemia.家族性高胆固醇血症的遗传和分子结构。
J Intern Med. 2023 Feb;293(2):144-165. doi: 10.1111/joim.13577. Epub 2022 Oct 17.
9
Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study.洛美他派长期治疗常染色体隐性高胆固醇血症的疗效:泛欧洲洛美他派研究的亚组分析
Front Genet. 2022 Aug 22;13:937750. doi: 10.3389/fgene.2022.937750. eCollection 2022.
10
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.脂蛋白(a)与动脉粥样硬化性心血管疾病及主动脉瓣狭窄:欧洲动脉粥样硬化学会共识声明。
Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361.